ENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Fudan University, Shanghai, 200031, PR China; NHC Key Laboratory of Hearing Medicine (Fudan University), Shanghai, 200031, PR China.
ENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Fudan University, Shanghai, 200031, PR China; NHC Key Laboratory of Hearing Medicine (Fudan University), Shanghai, 200031, PR China.
Int J Pediatr Otorhinolaryngol. 2023 Aug;171:111635. doi: 10.1016/j.ijporl.2023.111635. Epub 2023 Jun 12.
Hearing loss is a genetically heterogeneous disease with more than 100 genes identified. Pathogenic variants in the MPZL2 gene cause autosomal recessive non-syndromic hearing loss. MPZL2 patients showed mild to moderate progressive hearing loss with onset age around 10 years old. To date, four pathogenic variants have been identified.
To explore the clinical characteristics and variants of MPZL2-related hearing loss, and summarize the prevalence rate in overall hearing loss patients.
To determine the prevalence of MPZL2-related hearing loss in the Chinese population, we analyzed MPZL2 variants of whole exome sequencing data derived from a cohort of 385 hearing loss patients.
Overall, homozygous MPZL2 variants were identified in 5 sporadic cases (diagnostic rate = 1.30%). A novel missense variant c.52C > T;p.Leu18Phe was identified in one other patient with compound heterozygous mutations in MPZL2, but the pathogenicity was uncertain according to the American College of Medical Genetics guidelines (2015). A patient homozygous for the c.220C > T,p.Gln74Ter variant showed congenital profound hearing loss at all frequencies, a phenotype different from previous reports.
Our results enriched the mutation and phenotype spectrum of MPZL2-related hearing loss. Comparisons between allele frequencies of MPZL2:c.220C > T;p.Gln74Ter and other common deafness variants suggested that MPZL2:c.220C > T;p.Gln74Ter should be included in the group of common deafness variants for prescreening.
听力损失是一种遗传异质性疾病,已有超过 100 个基因被确定。MPZL2 基因的致病性变异导致常染色体隐性非综合征性听力损失。MPZL2 患者表现为 10 岁左右起病的轻度至中度进行性听力损失。迄今为止,已经发现了四个致病性变异。
探讨 MPZL2 相关听力损失的临床特征和变异,并总结其在所有听力损失患者中的患病率。
为了确定 MPZL2 相关听力损失在中国人群中的患病率,我们分析了来自 385 例听力损失患者的外显子组测序数据中的 MPZL2 变异。
总体而言,在 5 例散发性病例中发现纯合 MPZL2 变异(诊断率 = 1.30%)。在另一位患者中发现了一个新的错义变异 c.52C>T;p.Leu18Phe,该患者为 MPZL2 的复合杂合突变,但根据美国医学遗传学学院(2015 年)的指南,其致病性不确定。一位纯合 c.220C>T,p.Gln74Ter 变异的患者表现为所有频率的先天性重度听力损失,与以往报道的表型不同。
我们的研究结果丰富了 MPZL2 相关听力损失的突变和表型谱。MPZL2:c.220C>T,p.Gln74Ter 与其他常见耳聋变异的等位基因频率比较表明,MPZL2:c.220C>T,p.Gln74Ter 应被纳入常见耳聋变异的预筛查组。